Drug intelligence / Profile preview

ALT0135

Development stage: Preclinical
Lead developer: Alturos Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ALT0135 is an orally bioavailable, brain-penetrant small molecule lead candidate developed by Alturos Therapeutics for the treatment of Alzheimer's Disease. Currently in the IND/CTA-enabling stage, the compound is designed to address the underlying pathology of neurodegeneration. ALT0135 is part of a pipeline focused on modulating neuroinflammatory pathways and restoring homeostatic functions in the central nervous system. Based on the company's patent portfolio and therapeutic focus, the drug is identified as an inhibitor of p38 alpha mitogen-activated protein kinase (MAPK), a target implicated in the neuroinflammatory response and synaptic dysfunction associated with Alzheimer's pathology.

Other names: ALT-0135ALT0135ALT 0135

Targets

MAPK14 (p38 mitogen-activated protein kinase alpha)

Beyond the preview

Go deeper on ALT0135.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALT0135.

Explore the full profile